LXR

Liver X receptor

LXR

Related Products

LXRs (Liver X Receptor α and β) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. LXRs are oxysterol-activated transcription factors that upregulate a suite of genes that together promote coordinated mobilization of excess cholesterol from cells and from the body. The LXRs, like other nuclear receptors, are anti-inflammatory, inhibiting signal-dependent induction of pro-inflammatory genes by nuclear factor-κB, activating protein-1, and other transcription factors.

LXRα is expressed predominately in some tissues, including the liver, kidney, macrophages, and adipose tissue. However, LXRβ is ubiquitously expressed. Activating LXRα (mainly expressed in liver) results in high triglyceride production, and growing evidence suggests that selective LXRβ agonists can reduce this side effect.

LXR 관련 제품 (91)
Antibodies (1)

By Effects:	Inhibitors (10) Agonists (42) Degrader (1) Antagonists (17) Activators (11) Modulators (5) Inducer (1)

Cat. No.	상품명	효과	Purity	Chemical Structure

HY-160972

MM0299	Modulator	98.51%
MM0299 is a selective lanosterol synthase (LSS) inhibitor with an IC₅₀ value of 2.22 μM. MM0299 depletes intracellular cholesterol and acts as a growth inhibitor for glioma stem-like cells. MM0299 exhibits anti-glioblastoma activity. MM0299 is applicable to research related to glioblastoma.

HY-123402

GSK3987	Agonist	99.19%
GSK3987 is a pan LXRα/β agonist with EC₅₀s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation.

HY-111498

RGX-104 hydrochloride	Agonist	99.88%
RGX-104 hydrochloride is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene.

HY-101973

XL041	Agonist	98.80%
XL041 (BMS-852927) is an LXRβ-selective agonist.

HY-139576B

Larsucosterol trimethylamine	Antagonist
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1.

HY-77278

25-Hydroxytachysterol3	Agonist	98.07%
25-Hydroxytachysterol3 is the metabolite of Vitamin D3 (HY-15398). 25-Hydroxytachysterol3 inhibits the proliferation of epidermal keratinocytes and dermal fibroblasts, stimulates the expression of differentiation- and antioxidant-related genes in keratinocytes. 25-Hydroxytachysterol3 activates vitamin D receptor (VDR) and aryl hydrocarbon receptor (AhR), liver X receptor α/β (LXR α/β) and peroxisome proliferator-activated receptor γ (PPARγ), stimulates the expression of CYP24A1.

HY-33821

LXRβ ligand 1	Agonist	99.40%
LXRβ ligand 1 is a LXR β ligand-binding domain agonist, with an EC₅₀ of 57 μM and a K_i of 28 μM against human LXR β. LXRβ ligand 1 forms hydrogen bonds with His435, stabilizes the His-Trp activation switch, and locks the ligand-binding domain in an agonist conformation; its tert-butyl moiety occupies a hydrophobic subpocket, while its phenyl moiety forms a π-π stacking interaction with Phe329. LXRβ ligand 1 serves as a structural unit for the development of LXRβ modulators.

HY-N2078

Yamogenin	Antagonist	99.86%
Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes. Yamogenin is a steroidal saponin that can be obtained from plant species with in vitro cytotoxicity, antioxidant, and antimicrobial properties. Yamogenin induces cell death via the extrinsic and intrinsic way of apoptosis. Yamogenin inhibits protein denaturation with an IC₅₀ of 1421.92 μg/mL. Yamogenin can be studied in research on gastric cancer.

HY-19919

BMS-779788	Agonist	99.57%
BMS-779788 is a LXR partial agonist with IC₅₀ values of 68 nM for LXRα and 14 nM for LXRβ.

HY-123148

IMB-808	Agonist	99.84%
IMB-808 is a potent LXRα/β dual agonist with EC₅₀ values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1). IMB-808 can be used for the study of atherosclerosis research.

HY-W040150

(24S,25)-Epoxycholesterol	Agonist	98.10%
24S,25-Epoxycholesterol is an agonist for Liver X Receptor (LXR). 24S,25-Epoxycholesterol exhibits properties in regulating the cholesterol efflux, inhibiting tumor growth against gastric cancer and glioblastoma and inducing apoptosis in BMMC cells.

HY-124418

SBI-477	Inhibitor	98.0%
SBI-477 is a chemical probe that stimulates insulin signaling by deactivating the transcription factor MondoA. SBI-477 can lead to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes.

HY-N4247

Kuwanon G	Activator	99.45%
Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis.

HY-144549

LXR agonist 1	Agonist	99.95%
LXR (Liver X receptor) agonist 1 is potent LXR agonist with AC₅₀s of 1.5 nM and 12 nM for LXR-α and LXR-β, respectively. LXR agonist 1 has the potential for the research of atherosclerosis.

HY-128671

6-Thioinosine	Inhibitor	99.31%
6-Thioinosine (6TI) is a purine antimetabolite and an anti-adipogenic agent. 6-Thioinosine reduces the mRNA levels of PPARγ and C/EBPα and downregulates the mRNA levels of PPARγ target genes (LPL, CD36, aP2, and LXRα). 6-Thioinosine exerts its anti-adipogenic effects by downregulating PPARγ through JNK-dependent iNOS upregulation. 6-Thioinosine can be used to study adipocyte dysfunction.

HY-160038

GAC0003A4	Degrader
GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies.

HY-N2509

Iristectorigenin B	Agonist	99.48%
Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β.

HY-109073

Rovazolac	Modulator	98.04%
Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1.

HY-160039

GAC0001E5	Antagonist	98.01%
GAC0001E5 is an LXR inverse agonist. GAC0001E5 has antiproliferative activity and can be used in cancer research.

HY-125772

Acetyl podocarpic acid anhydride	Agonist	99.0%
Acetyl podocarpic acid anhydride is a potent, semisynthetic liver X receptor(LXR) agonist derived from extracts of the mayapple. Acetyl podocarpic acid anhydride has the potential to be useful for the prevention and research of atherosclerosis, especially in the context of low HDL levels.

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

LXR

LXR

LXR 관련 제품 (91)

Antibodies (1)

LXR 관련 제품 (91):